Not yet recruitingInterventionalPhase 2Last updated Aug 10, 2026

Pirfenidone as Treatment of Chronic Pancreatitis

Evaluation of Pirfenidone as a Novel Therapeutic Strategy Against Chronic Pancreatitis.

Overview

ClinicalTrials.gov ID: NCT07755813
Lead Sponsor: Vikas DudejaOTHER
Brief Summary: The proposed project is focused towards evaluation of Pirfenidone as a novel therapeutic strategy in patients with chronic pancreatitis (CP).
Study Type: Interventional

Interventions

Drug: Pirfenidone 267 mg Oral TabletDrug: PlaceboOther: PROMIS-Global HealthOther: Comprehensive Pain Assessment ToolOther: Brief Pain InventoryOther: Pancreatitis Quality of Life Instrument

Status

Overall Status: Not yet recruiting
Start Date: Aug 2026Estimated
Primary Completion Date: Aug 2030Estimated
Completion Date: Aug 2030Estimated

Study Record Dates

First Submitted: Aug 4, 2026
First Submitted that Met QC Criteria: Aug 4, 2026
First Posted: Aug 10, 2026Actual
Last Update Submitted that Met QC Criteria: Aug 4, 2026
Last Update Posted: Aug 10, 2026Actual
Last Verified: Aug 2026

NCT06253117Recruiting

Evaluation of Pirfenidone as a Novel Therapeutic Strategy Against Recurrent Acute Pancreatitis.

NCT05350371Recruiting

Safety and Tolerability of Pirfenidone in Acute Pancreatitis

NCT00063583Completed

Pirfenidone: A New Drug to Treat Kidney Disease in Patients With Diabetes

NCT02496182Unknown status

Pirfenidone in the Chronic Hypersensitivity Pneumonitis Treatment

NCT04099407Completed

Pirfenidone and Advanced Liver Fibrosis.

NCT00080223Completed

Safety Study of Oral Pirfenidone in Patients With Pulmonary Fibrosis/Idiopathic Pulmonary Fibrosis